CEFTAZIDIME TEVA 1 G

国: イスラエル

言語: 英語

ソース: Ministry of Health

有効成分:

CEFTAZIDIME AS PENTAHYDRATE

から入手可能:

ABIC MARKETING LTD, ISRAEL

ATCコード:

J01DD02

医薬品形態:

POWDER FOR SOLUTION FOR INJECTION

構図:

CEFTAZIDIME AS PENTAHYDRATE 1 G/VIAL

投与経路:

I.V, I.M

処方タイプ:

Required

製:

VIANEX S.A., GREECE

治療群:

CEFTAZIDIME

治療領域:

CEFTAZIDIME

適応症:

Treatment of single or multiple infections caused by susceptible microorganisms.

承認日:

2015-06-30

情報リーフレット

---
---
העדוה
העדוה
לע
לע
הרמחה
הרמחה
(
(
עדימ
עדימ
ןולעב )תוחיטב
ןולעב )תוחיטב
ל
ל
אפור
אפור
ןכדועמ(
ןכדועמ(
05.2013
05.2013
)
)
ךיראת
_______
NOVEMBER 24, 2014
__
םש
רישכת
תילגנאב
רפסמו
םושירה
CEFTAZIDIME TEVA POWDER FOR SOLUTION FOR INJECTION
1G: 143 79 31599 00; 2G: 143 78 31600 00
םש
לעב
םושירה
קיבא
קוויש .ד.ת ,מ"עב
8077
הינתנ
_
ספוט
הז
דעוימ
טורפל
תורמחהה
דבלב
!
תורמחהה
תושקובמה
קרפ
ןולעב
טסקט
יחכונ
טסקט
שדח
INDICATION
CONTRAINDICATIONS
History of severe hypersensitivity (e.g. anaphylactic
reaction) to any other type of beta-lactam antibacterial
agent (penicillins, monobactams and carbapenems).
POSOLOGY, DOSAGE & ADMINISTRATION
SPECIAL WARNINGS AND SPECIAL
PRECAUTIONS FOR USE
As with all beta-lactam antibacterial agents, serious
and occasionally fatal hypersensitivity reactions have
been reported. In case of severe hypersensitivity
reactions, treatment with ceftazidime must be
discontinued immediately and adequate emergency
measures must be initiated
Ceftazidime has a limited spectrum of antibacterial
activity. It is not suitable for use as a single agent for the
treatment of some types of infections unless the
pathogen is already documented and known to be
susceptible or there is a very high suspicion that the
most likely pathogen(s) would be suitable for treatment
with ceftazidime. This particularly applies when
considering the treatment of patients with bacteraemia
and when treating bacterial meningitis, skin and soft
tissue infections and bone and joint infections. In
addition, ceftazidime is susceptible to hydrolysis by
several of the extended spectrum beta lactamases
(ESBLs). Therefore information on the prevalence of
ESBL producing organisms should be taken into account
when selecting ceftazidime for treatment.
INTERACTION WITH OTHER
MEDICAMENTS AND OTHER FORMS OF
INTERACTION
EFFECTS ON ABILITY TO DRIV

製品の特徴

CEFTAZIDIME TEVA, 7. 6. 2015, RH
."רשואו קדבנ ונכותו תואירבה דרשמ י"ע
עבקנ הז ןולע טמרופ"
ינוי :רשואמ ןולע
2015
“This leaflet format has been determined by the Ministry of Health
and the content thereof has been
checked and approved.” Date of approval: June 2015
CEFTAZIDIME TEVA
POWDER FOR SOLUTION FOR INJECTION
FORMULATION AND STRENGTH
Ceftazidime Teva 1g or 2 g, sterile powder for solution for injection.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Injection bottle containing ceftazidime pentahydrate, equivalent to 1
g and 2 g of
ceftazidime.
_Other Ingredients _
Sodium carbonate (anhydrous) (E500).
PHARMACEUTICAL FORM
Ceftazidime Teva 1 g powder for solution for i.v./i.m. injection.
Ceftazidime Teva 2 g powder for solution for i.v. injection.
CLINICAL INFORMATION
INDICATIONS
Treatment of single or multiple infections caused by susceptible
microorganisms.
In meningitis it is recommended that the results of a sensitivity test
are known before
treatment with ceftazidime as a single agent.
It may be used for infections caused by organisms resistant to other
antibiotics
including aminoglycosides and many cephalosporins.
When appropriate, however, it may be used in combination with an
aminoglycoside
or most other β-lactam antibiotics for example, in the presence of
severe neutropenia,
or with an antibiotic active against anaerobes when the presence of
_Bacteroides fragilis _
is suspected. In addition, ceftazidime is indicated in the
perioperative prophylaxis of
transurethral prostatectomy.
_INDICATIONS INCLUDE: _
-
severe infections in general
-
respiratory tract infections including lung infections in cystic
fibrosis
-
ear, nose and throat infections
-
urinary tract infections
-
skin and soft tissue infections
-
gastrointestinal, biliary and abdominal infections
-
bone and joint infections
-
Dialysis: infections
associated
with
haemo-
and
peritoneal
dialysis
and
with
continuous ambulatory peritoneal dialysis (CAPD).
DOSAGE AND ADMINISTRATION
Ceftazidime is to